PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenScript Corporation Finishes Year with Successful Hong Kong IPO - Funds to Expand R&D, Services and Products, and Production -
GenScript Corporation Finishes Year with Successful Hong Kong IPO


NewswireToday - /newswire/ - Piscataway, NJ, United States, 2016/01/14 - Funds to Expand R&D, Services and Products, and Production - 1548:HK

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


GenScript Biotech Corporation, the number one global provider of gene synthesis services and a strong player in synthetic biology, ended 2015 with a successful IPO of 400,000, 000 shares on the Hong Kong Stock Exchange, raising $67.2 million. Haitong International Capital Limited served as the sole sponsor. Haitong International Securities Company Limited and J.P. Morgan Securities (Asia Pacific) Limited served as joint global coordinators; and Haitong International Securities Company Limited, J.P. Morgan Securities (Asia Pacific) Limited (in relation to the Hong Kong public offering) and J.P. Morgan Securities plc (in relation to the international offering) served as joint bookrunners for the offering, which closed on December 30, 2015. The company stock trades under the symbol 1548:HK.

Founded in 2002 in Piscataway, New Jersey, and headquartered in Nanjing, China, GenScript ranks number one in the worldwide gene synthesis services market. The company will use the funds to expand research and development, offer new services and products, and increase production capabilities.

"The over-booked offering and the stock’s upward momentum highlight our unique global leadership position and the continued growing interest in the synthetic biology and other biomedical fields that we serve," said GenScript CEO Frank Zhang, Ph.D. "These funds enable us to significantly improve the ways we serve biopharmaceutical and synthetic biology companies and researchers around the world, improve how research is conducted, and address some of humanity’s most difficult healthcare challenges."

With the global headquarters in Nanjing, China, GenScript maintains a major facility for research, development and production in the Jiangning Science Park, Nanjing, China. The company markets its products in more than 100 countries, with more than 50 percent of sales coming from the North America.

About GenScript

GenScript ( is the world leader in gene synthesis and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development, and synthetic biology. Since its founding in 2002, GenScript has provided services and products to scientists in more than 100 countries worldwide. The company delivers biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, in vitro and in vivo pharmacology and industrial synthetic biology products.

Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, including, without limitation, statements related to the earning and sales forecasts. These forward-looking statements are based upon GenScript’s current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: market condition, global stability, new technologies. The forward-looking statements made in this press release speak only as of the date of this press release. GenScript expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GenScript’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contact: Karl Schmieder - messagingLAB
P: 646-515-3392 - E: genscript[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: GenScript Corporation


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

GenScript Corporation Finishes Year with Successful Hong Kong IPO

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GenScript Biotech Corp. |
Publisher Contact: Sally Wang - 
732-885-9188 x111[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From GenScript Corporation / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business




  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (